Advertisement

Topics

Community Acquired Pneumonia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

22:35 EDT 7 Aug 2017 | BioPortfolio Reports

DelveInsight's, Community Acquired Pneumonia Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Community Acquired Pneumonia. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Community Acquired Pneumonia. This report provides information on the therapeutic development for Community Acquired Pneumonia, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Aridis Pharmaceuticals LLC; BioAegis Therapeutics Inc; Biotest AG; InflaRx GmbH; ioGenetics Inc; Kyorin Pharmaceutical Co Ltd; Lascco SA; Melinta Therapeutics Inc; Merck Co Inc; Nabriva Therapeutics AG; Paratek Pharmaceuticals Inc; TaiGen Biotechnology Co Ltd; Takeda Pharmaceutical Company Ltd; Tetraphase Pharmaceuticals Inc; TiGenix NV; Wockhardt Ltd
Community Acquired Pneumonia Pipeline Drugs
Community Acquired Pneumonia Pipeline Assessment
Community Acquired Pneumonia Pipeline Analysis
Community Acquired Pneumonia Drugs under Development
Community Acquired Pneumonia Discovery drugs
Community Acquired Pneumonia Preclinical drugs
Community Acquired Pneumonia Phase I drugs
Community Acquired Pneumonia Phase II drugs
Community Acquired Pneumonia Phase III Pipeline Drugs Assessment
Community Acquired Pneumonia Preregistration drugs
Community Acquired Pneumonia Molecules in pipeline

Original Article: Community Acquired Pneumonia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Community Acquired Pneumonia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Quick Search
Advertisement
 

Relevant Topics

Pneumonia
Pneumonia (bronchopneumonia, lobar pneumonia and double pneumonia) is inflammation (swelling) of the tissue in one or both of your lungs. It is usually caused by an pneumococcal infection caused by bacteria called Streptococcus pneumoniae.  However,...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...